EX-10.1 5 ex10-1.htm

 

Exhibit 10.1

 

INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT

 

This INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT (this “Agreement”), dated as of May 17, 2021 (the “Effective Date”), is made between SPINALCYTE LLC, a Texas limited liability company (“SpinalCyte”) and FIBROBIOLOGICS LLC, a Texas limited liability company (“FibroBiologics”). FibroBiologics and SpinalCyte are each referred to individually as a “Party” and collectively as the “Parties.”.

 

WHEREAS, SpinalCyte owns 100% of the rights, title and interest in the SpinalCyte Licensed IP (as defined below);

 

WHEREAS, SpinalCyte desires to grant and FibroBiologics desires to accept an exclusive license to FibroBiologics to practice the SpinalCyte Licensed IP in a limited field of use;

 

WHEREAS, FibroBiologics owns 100% of the rights, title and interest in the FibroBiologics Licensed IP (as defined below); and

 

WHEREAS, FibroBiologics desires to grant and SpinalCyte desires to accept an exclusive license to SpinalCyte to practice the FibroBiologics Licensed IP in a limited field of use.

 

NOW THEREFORE, in consideration of the ongoing financial and other support provided by FibroBiologics to SpinalCyte and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, FibroBiologics and SpinalCyte hereby agree as follows:

 

ARTICLE 1 DEFINITIONS

 

“Affiliate” means, with respect to a Party, any Person that controls, is controlled by, or is under common control with such Party, where “control” means the possession, directly or indirectly, through one or more intermediaries, of the power to direct or cause the direction of the management or policies of a Person, whether through ownership of voting securities, controlling interests or similar arrangement.

 

“Exploit” means to make, have made, import, use, sell or offer for sale, including to research, develop, commercialize, register, manufacture, have manufactured, hold or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market, sell, have sold, dispose of, copy, distribute, create derivative works of, publicly perform or publicly display.

 

“FibroBiologics Licensed Field of Use” means, collectively, the diagnosis, treatment, prevention and palliation of (a) spinal diseases, disorders or conditions, (b) cancer, (c) orthopedics diseases, disorders or conditions and (4) multiple sclerosis.

 

“FibroBiologics Licensed IP” means the intellectual property set forth and described in Schedule 1 to this Agreement.

 

“FibroBio/ogics Licensed Product(s)” means any product, process or service that incorporates, utilizes or is made with the use of the SpinalCyte Licensed IP.

 

“Licensed IP” means the FibroBiologics Licensed IP and the SpinalCyte Licensed IP, collectively.

 

-1-

 

 

“Licensee” means the Party receiving rights under a license grant pursuant to this Agreement. Depending on the context, Licensee may mean either or both of SpinalCyte and FibroBiologics.

 

“Patent Owner” means the owner of a patent within the Licensed IP. Depending on the context, Patent Owner may mean either or both of SpinalCyte and FibroBiologics.

 

“Person” means an individual, corporation, partnership, joint venture, limited liability company, governmental authority, unincorporated organization, trust, association or other entity.

 

“Prosecute and Maintain” means with regard to a patent, the preparing, filing, prosecuting and maintenance of such patent, as well as handling re-examinations and reissues with respect to such patent, together with the conduct of interferences, the defense of oppositions and other similar proceedings with respect to the particular patent. For clarification, Prosecute and Maintain does not include any other enforcement actions taken with respect to a patent.

 

“SpinalCtye Licensed Field of Use” means any and all fields of use other than the FibroBiologics Licensed Field of Use, and specifically includes (without limitation) Alzheimer’s and other dementia related diseases, diabetes, cachexia, tissue regeneration, stroke, addiction, miscarriages, inflammatory bowel disease, transplant rejections, cerebral palsy, sclerosing cholangitis, Parkinson’s disease, erectile dysfunction, allergy, asthma, concussive neurological damage, encephalopathy, blindness, aneurysms, ovarian failure, dysbiosis, cerebral hemorrhage, acute respiratory distress syndrome, COVID, pathological immune response, dental/periodontal, and alopecia.

 

“Spina/Cyte Licensed IP” means the intellectual property set forth and described in Schedule 2 to this Agreement.

 

“Spina/Cyte Licensed Product(s)” means any product, process or service that incorporates, utilizes or is made with the use of the FibroBiologics Licensed IP.

 

ARTICLE 2 LICENSE GRANTS

 

Spina/Cyte License Grant to Fibrobiologics. Subject to the terms and conditions of this Agreement, SpinalCyte hereby grants to FibroBiologics, and FibroBiologics hereby accepts, a worldwide, perpetual, irrevocable, fully paid up, royalty-free, exclusive, transferable, sub-licensable license to the SpinalCyte Licensed IP, to Exploit Licensed Product(s) in the FibroBiologics Licensed Field of Use.

 

FibroBiologics License Grant to Spina/Cyte. Subject to the terms and conditions of this Agreement, FibroBiologics hereby grants to SpinalCyte, and SpinalCyte hereby accepts, a worldwide, perpetual, irrevocable, fully paid up, royalty-free, exclusive, transferable, sub licensable license to the FibroBiologics Licensed IP, to Exploit Licensed Product(s) in the SpinalCyte Licensed Field of Use.

 

Exclusivity. For the avoidance of doubt, the licenses in Section 2.1 and Section 2.2 are exclusive within their respective fields of use even as to the granting licensor.

 

No Implied Licenses. Except as otherwise specifically set forth herein, only the licenses granted pursuant to the express terms of this Agreement shall be of any legal force and effect. No license or other intellectual property rights shall be created by implication in any patents, technology and/or proprietary information owned by a Party, even if such patents, technology, or proprietary information is necessary to exploit the Licensed IP.

 

-2-

 

 

ARTICLE 3

PATENT PROSECUTION AND MAINTENANCE; PATENT ENFORCEMENT

 

Patent Prosecution and Maintenance. Each Party, as Patent Owner, shall diligently and in good faith Prosecute and Maintain any and all patent applications and patents owned by such Party that are included in the Licensed IP, at its own cost. If a Patent Owner decides not to: (i) prosecute certain patent applications within the Licensed IP to issuance or (ii) maintain any United States or foreign issued patent within the Licensed IP, the Patent Owner shall timely notify the Licensee of such patent right in writing thereof and upon written request by the Licensee, the Parties shall cooperate to transfer the ownership of such patent right to the Licensee, provided, that the Patent Owner shall retain an a worldwide, irrevocable, fully paid up, royalty-free, exclusive, transferable, sublicensable license to and under the transferred patent right to Exploit Licensed Products in its field of use. The preceding sentence shall not apply to any patent applications within the Licensed IP that will be abandoned for the pursuit of a utility application in the case of a provisional application, a divisional or continuation application in the case of any utility application, any national stage applications in the case of a patent cooperation treaty application, or countries not validated in the case of a European or other regional patent application.

 

Infringement Procedures. During the term of this Agreement, each Party shall promptly inform the other of any suspected infringement, misuse, misappropriation, theft or breach of confidence of other proprietary rights in the Licensed IP by a third party (collectively “Third Party Activities”), and with respect to such activities as are suspected. For Third Party Activities involving a Licensee’s exclusive field of use, the Licensee shall have the first right, but not the obligation, to institute an action or proceeding against Third Party Activities and defend any declaratory judgment action relating thereto. The Patent Owner shall have the right, but not the obligation, to join any such suit, legal action or proceeding that is initiated by the Licensee, at the Licensee’s cost. The Patent Owner shall, where necessary, furnish a power of attorney solely for such purpose, or be named as a necessary party to, such action, at the Licensee’s cost. If the Licensee fails to bring such an action or proceeding within the earlier of (a) a period ofthree (3) months after receiving notice or otherwise having knowledge of such Third Party Activities, or (b) thirty (30) days before the time limit, if any, set forth in the applicable law or regulations for the filing of or response to such suit action or proceeding, whichever comes first, then the Patent Owner shall have the right, but not the obligation, to prosecute the same solely with respect to the activities at its own expense. The Party not instituting the action or the proceeding (the “Non-Instituting Party”) will reasonably cooperate with the Party instituting the action or the proceeding (the “Instituting Party”) in such action. In addition, notwithstanding anything to the contrary contained herein, if the Non-Instituting Party cooperates in such action, such cooperation shall be at the Instituting Party’s sole expense. Should either the Patent Owner or the Licensee commence action under the provisions of this Section 3.2 and thereafter elect to abandon the same, it shall give timely notice to the other Party who may, if it so desires, continue prosecution of such action or proceeding. All recoveries, whether by judgment, award, decree or settlement, from infringement or misuse of Licensed IP under this Section 3.2 shall be apportioned as follows: (a) the Instituting Party shall first recover an amount equal the costs and expenses incurred by such Party directly related to the prosecution of such action or proceeding, (b) the Non-Instituting Party shall then recover costs and expenses incurred by such Party, if any, directly related to its cooperation in the prosecution of such action or proceeding and (c) the remainder shall be shared by the Parties, with the Party bringing the action allocated eighty percent (80%) and the Party cooperating in such action allocated twenty percent (20%) of such amounts, such amount not to exceed $1,000,000.

 

Consent to Settle. Neither Party shall settle any action covered by Section 3.2 without first obtaining the consent of the other Party, which consent will not be unreasonably withheld.

 

Defense oflnfringement Claims. If any third party asserts a claim, demand, action, suit or proceeding against a Licensee (or any of its sublicensees), alleging that any Licensed Product or that the use or practice of the Licensed IP infringes, misappropriates or violates the intellectual property rights of any Person (any such claim, demand, action, suit or proceeding being referred to as and “Infringement Claim”), the Licensee shall promptly notify the Patent Owner in writing specifying the facts, to the extent known, in reasonable detail. In the case of any such Infringement Claim, the Licensee shall assume control of the defense and shall have the exclusive right to settle any Infringement Claim against the Licensee without the consent of the Patent Owner; provided, however, if such settlement requires any payment from the Patent Owner or decreases the Patent Owner’s rights under this Agreement, the Licensee shall be required to obtain the Patent Owner’s consent, which consent will not be unreasonably withheld.

 

-3-

 

 

ARTICLE 4 TERM

 

Term. This Agreement shall commence upon the Effective Date and expire, on a country-by-country basis, on the date of expiration of the last valid claim of the patent rights in the Licensed IP.

 

ARTICLE 5 INDEMNIFICATION

 

FibroBio/ogics Indemnity. FibroBiologics shall indemnify, defend, and hold harmless SpinalCyte, its Affiliates, and their respective shareholders, members, managers, directors, officers, employees, personnel and agents (collectively, the “SpinalCyte Indemnified Parties” and each an “Spina/Cyte Indemnified Party”) from and against all claims, actions, causes of action or demands, (including liabilities, costs, expenses, reasonable attorneys’ fees, damages and losses resulting from the foregoing) (collectively, “Claims”) brought by or on behalf of a third party arising out of or in connection with: (a) any violation of applicable law by FibroBiologics, its Affiliates or its sublicensees; (b) any claim that a FibroBiologics Licensed Product or that the use of the SpinalCyte Licensed IP by Fibrobiologics, its Affiliates or its sublicensees infringes, misappropriates or otherwise violates any intellectual property rights of any third party; and (c) FibroBiologics’s, its Affiliates or its sublicensses gross negligence, willful misconduct or fraudulent conduct. FibroBiologics shall not be responsible to, nor shall it indemnify any SpinalCyte Indemnified Party for any Claims to the extent arising from any negligent act or omission or willful misconduct of an SpinalCyte Indemnified Party and its shareholders, members, managers, directors, officers, employees, personnel and agents, and those for whom in law SpinalCyte is responsible for. This Section 5.1 shall survive any termination or expiration of this Agreement.

 

SpinalCyte Indemnity. SpinalCyte shall indemnify, defend, and hold harmless FibroBiologics, its Affiliates, and their respective shareholders, members, managers, directors, officers, employees, personnel and agents (collectively, the “FibroBiologics Indemnified Parties” and each a “FibroBiologics Indemnified Party”) from and against any Claims brought by or on behalf of a third party arising out of or in connection with: (a) any violation of applicable law by SpinalCyte, its Affiliates or its sublicensees; (b) any claim that a SpinalCyte Licensed Product or that the use of the FibroBiologics Licensed IP by SpinalCyte, its Affiliates or its sublicensees infringes, misappropriates or otherwise violates the intellectual property rights of any third party; (c) SpinalCyte’s, its Affiliates’ or its sublicensees gross negligence, willful misconduct or fraudulent conduct. SpinalCyte shall not be responsible to, nor shall it indemnify a FibroBiologics Indemnified Party for any Claims to the extent arising from any negligent act or omission or willful misconduct of FibroBiologics, its Affiliates, and those for whom in law FibroBiologics is responsible for. This Section 5.2 shall survive any termination or expiration of this Agreement.

 

Procedure. The indemnified Party shall promptly notify the indemnifying Party in writing of any Claim for which it believes it is entitled to indemnification hereunder. Failure or delay in providing such notice shall not relieve the indemnifying Party of its indemnification obligations, except to the extent the indemnifying Party demonstrates that the defense or settlement of the Claim has been prejudiced thereby. Subject to prov1s1ons below in this Section 5.3, the indemnifying Party shall have the right to control the defense and settlement of any Claim, or may at any time tender control of the defense or settlement of such Claim to the indemnified Party. The indemnified Party shall have the right to approve of counsel retained by the indemnifying Party for such Claim (such approval not to be unreasonably withheld, conditioned or delayed), and may, at its own cost, elect to participate in the defense or settlement of any Claim with counsel of its choice. No compromise or settlement other than solely for an amount of money may be committed to by the indemnifying Party without the indemnified Party’s prior written approval (which shall not be unreasonably withheld, conditioned or delayed).

 

-4-

 

 

ARTICLE 6 LIMITATION OF LIABILITY

 

WAIVER OF CONSEQUENTIAL DAMAGES. EXCEPT WITH RESPECT TO EACH PARTY’S INDEMNIFICATION OBLIGATIONS PURSUANT TO ARTICLE 5, FRAUD OR INTENTIONAL MISCONDUCT, IN NO EVENT SHALL EITHER PARTY, ITS DIRECT OR INDIRECT SUBSIDIARIES, AFFILIATES, DIRECTORS, OFFICERS, AGENTS, EMPLOYEES OR REPRESENTATIVES BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES OF ANY KIND, NOR FOR ANY LOST PROFITS OR REVENUES, IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT.

 

LIMITATION OF LIABILITY. EXCEPT FOR EACH PARTY’S INDEMNIFICATION OBLIGATIONS PURSUANT TO ARTICLE 5, OR GROSS NEGLIGENCE OR FRAUD OR INTENTIONAL MISCONDUCT, THE MAXIMUM AGGREGATE LIABILITY OF EITHER PARTY TO THE OTHER, FOR ANY REASON AND UPON ANY CAUSE OF ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE LIMITED TO AN AMOUNT NOT TO EXCEED $1,000,000, EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR SUCH DAMAGES ARE REASONABLY FORESEEABLE. THE FOREGOING LIMITATIONS SHALL APPLY REGARDLESS OF THE CAUSE OR FORM OF ACTION, WHETHER BASED IN CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY, WARRANTY OR OTHERWISE AND SHALL: NEVER BE DEEMED TO FAIL IN THEIR ESSENTIAL PURPOSE.

 

ARTICLE 7 CONFIDENTIALITY

 

Definition. For purposes of this Agreement, “Confidential Information” of a Party means any non-public information or materials belonging to, concerning or in the possession or control of such Party or its Affiliates (the “Disclosing Party”) that is furnished, disclosed or otherwise made available (directly or indirectly) to the other Party (or Persons acting on such other Party’s behalf) (the “Receiving Party”) in connection with this Agreement and which is either marked or identified as confidential or proprietary or is of a type that a reasonable person would recognize it to be confidential or proprietary.

 

-5-

 

 

Confidentiality Obligations. During the term and for a period of two (2) years thereafter, or in the event an item is a trade secret, so long as the item remains a trade secret, the Receiving Party shall: (a) hold the Confidential Information in strict confidence and avoid the disclosure thereof to any third party by using the same degree of care as it uses to avoid the unauthorized use or disclosure of its own Confidential Information of a similar nature, but not less than reasonable care; and (b) not use the Confidential Information for any purpose except as contemplated under this Agreement. Should a Party become possessed of a trade secret of a Disclosing Party underthe terms of this Agreement, the Receiving Party shall not, during the term and thereafter, use or disclose such trade secret. The Receiving Party shall restrict the possession and use of Confidential Information to its personnel who have a need to know and are bound by confidentiality obligations no less stringent than those contained herein. The Receiving Party may disclose Confidential Information as required by applicable law, provided the Receiving Party discloses only such information as is required by applicable law and, if permitted by applicable law, uses reasonable efforts to notify the Disclosing Party of such disclosure in sufficient time to allow the Disclosing Party to seek a protective order or similar confidential treatment at Disclosing Party’s expense. The Receiving Party shall promptly notify the Disclosing Party of any facts known to the Receiving Party regarding any unauthorized disclosure or use of Confidential Information. Each Party acknowledges that its breach of the obligations set forth in this Section 7.2 may cause irreparable harm for which the other Party shall be entitled to seek injunctive or other equitable relief. All Confidential Information shall remain the exclusive property of the Disclosing Party.

 

Limitations. Confidential Information shall not include any information that: (a) was demonstrably known by the Receiving Party before disclosure by the Disclosing Party, (b) becomes generally publicly known or otherwise known to the Receiving Party after such disclosure, other than by breach of a confidentiality obligation; or (c) is independently developed by the Receiving Party by persons without access to such information.

 

Return or Destruction of Confidential Information. Upon termination of this Agreement for any reason or upon the other Party’s written request, each Party shall promptly:

 

(a) return or destroy, at the other Party’s direction, all material embodying the Confidential Information of the other Party in such Party’s possession, custody or control; and (b) if requested by the other Party, deliver an affidavit certifying that such Party has complied with the obligations set forth herein.

 

Residual Rights. Each Party acknowledges and agrees that the other Party, its Affiliates and their respective employees and agents shall be free to use and employ their general skills, ideas, concepts, know-how and expertise, and to use, disclose, and employ any generalized ideas, concepts, know-how, methods, techniques or skills gained or learned during the course of any activities performed hereunder, subject to its obligations respecting the other Party’s Confidential Information pursuant to this Article 7.

 

-6-

 

 

ARTICLE 8 REPRESENTATIONS AND WARRANTIES.

 

Mutual Representations and Warranties. Each Party represents and warrants to the other that they each have: (a) all requisite legal and corporate power to execute and deliver this Agreement; (b) taken all corporate action necessary for the authorization, execution and delivery of this Agreement; (c) no agreement or understanding with any third party that interferes with or will interfere with the performance of their respective obligations under this Agreement; (d) obtained and shall maintain all rights, approvals and consents necessary to perform their respective obligations under this Agreement; (e) taken all action required or necessary to make such agreements legal, valid and binding obligations upon them; and (f) it has the right to grant the licenses to the other which are granted in this Agreement.

 

Disclaimer. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, WHETHER EXPRESS OR IMPLIED, EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS SECTION 8.1, AND EACH PARTY EXPRESSLY DISCLAIMS ANY IMPLIED OR STATUTORY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, QUALITY, TITLE OR ANY REPRESENTATION OR WARRANTY ARISING FROM COURSE OF PERFORMANCE, COURSE OF DEALING OR USAGE OF TRADE.

 

ARTICLE 9 ADDITIONAL PROVISIONS

 

Further Assurances. Each Party covenants and agrees to execute and deliver or cause to be executed and delivered to the other Parties such instruments or further assurances as may, in the reasonable opinion of such other Party, be necessary or desirable to give effect to the provisions of this Agreement.

 

Notices. All notices required or permitted under this Agreement shall be in writing and delivered via overnight mail or overnight courier service, signature proof of receipt required. Notices shall be directed to the addresses set forth below and shall be deemed effective upon receipt. Either Party may change its address for notices from time to time by providing written notice to the other Party.

 

If to SpinalCyte:

 

President of SpinalCyte PO Box 891146

Houston, Texas 77289

 

-7-

 

 

If to FibroBiologics:

 

President of SpinalCyte PO Box 891146

Houston, Texas 77289

 

Assignment. The Agreement shall be binding on the Parties and their successors and permitted assigns. Neither Party shall assign, transfer or delegate any of its rights, duties or obligations under this Agreement, or any part thereof, whether by operation of law or otherwise, without the prior written consent of the other Party, provided that either Party shall be entitled to assign or transfer this Agreement in connection with the sale or acquisition of its business to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. Any assignment in violation of this paragraph shall be void ab initio.

 

Publicity; Press Releases. Neither Party shall, without the prior written consent of the other Party which shall not be unreasonably withheld, issue any press releases or make any public statements concerning the existence of or activities under this Agreement or disclose the terms of this Agreement to any third party other than its legal, financial and other advisors under a duty of confidentiality. The Parties will mutually agree upon the content and timing of any press release announcing the execution of this Agreement or otherwise relating to the terms of this Agreement.

 

Modifications; Waiver. This Agreement may be modified only pursuant to a writing executed by authorized representatives of both Parties. The Parties expressly disclaim the right to claim the enforceability of any oral modifications to this Agreement or any amendments based on course of dealing, waiver, reliance, estoppel or other similar legal theory. No delay or omission by either Party to exercise any right occurring upon any non-compliance or default of the other Party with respect to any of the terms of this Agreement shall impair any such right or be construed to be a waiver thereof.

 

No Third Party Beneficiaries. This Agreement is for the sole benefit of the Parties and their successors and permitted assigns and nothing herein, express or implied, shall give or be construed to give any Person other than the Parties any legal or equitable rights hereunder.

 

Severability. In the event any provision of this Agreement is determined by a court of competent jurisdiction to be invalid or unenforceable under applicable law, such provision shall be amended and interpreted to accomplish the objectives of such provision to the greatest extent possible under applicable law, and the remaining provisions of this Agreement shall continue in full force and effect.

 

Arbitration. The Parties agree that any and all disputes, claims or controversies arising out of or related to this Agreement, including any claims under any statute or regulation (“Disputes”), shall be submitted first to non-binding mediation. If the Disputes are not resolved through mediation, then, upon the election of either Party, the Disputes shall be submitted for binding arbitration. Unless the Parties agree otherwise, any mediation and arbitration shall take place in the State of Texas, Harris County, and shall be administered by, and pursuant to the rules of, the American Arbitration Association (“AAA”).

 

-8-

 

 

Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of New York, without reference to the principles of conflicts of law that would apply the substantive laws of another jurisdiction. In the event a court or other tribunal of competent jurisdiction rules that Section 9.9 or any provision therein is invalid or otherwise unenforceable, each Party hereby submits to the exclusive jurisdiction of the state and federal courts located in [Harris County, Texas] over any Disputes arising out of or relating to this Agreement and waives the right to object to such venue or make a claim offorum non conveniens. Notwithstanding the foregoing, nothing herein shall prevent either Party from commencing an action for the purpose of seeking immediate injunctive relief in the appropriate jurisdiction.

 

Survival. Any·provision of this Agreement that contemplates performance or observance subsequentto any expiration or termination of this Agreement, or which is otherwise necessary to interpret the respective rights and obligations of the Parties hereunder, shall survive any expiration or termination of this Agreement and continue in full force and effect, including without limitation Article 1 (General), Article 5 (Indemnification), Article 6 (Limitation of Liability), Article 7 (Confidentiality), and Article 9 (Additional Provisions).

 

Headings; Construction. The headings of the various sections in this Agreement are for convenience of reference only and shall not affect the construction or interpretation of this Agreement or this Agreement. The Parties acknowledge and agree that any principle of construction or rule of law that provides that an agreement shall be construed against the drafter of the agreement in the event of any inconsistency or ambiguity in such agreement shall not apply to the terms and conditions of this Agreement.

 

Entire Agreement. This Agreement, together with the Schedules attached hereto, sets forth the entire and exclusive agreement between the Parties as to the subject matter hereof and supersedes all prior and contemporaneous understandings, negotiations and agreements, written or oral, between the Parties.

 

Counterparts. This Agreement may be executed in several counterparts, including by e-mail and with electronic signatures, each of which will be deemed an original, and all of which taken together shall constitute one single agreement between the Parties with the same effect as if all the signatures were upon the same instrument. An electronic signature shall be as legally effective as an original signature.

 

[SIGNATURE PAGE FOLLOWS]

 

-9-

 

 

IN WITNESS WHEREOF, the Parties have duly executed and delivered this Agreement as of the date first above written.

 

FIBROBIOLOGICS LLC
     
By: /s/ Pete O’Heeron  
Name: Pete O’Heeron  
Title: Manager  
     
SPINALCYTE LLC
     
By: /s/ Pete O’Heeron  
Name: Pete O’Heeron  
Title: CEO  

 

-10-

 

 

Schedule 1

 

FibroBiologics Licensed IP

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0002AU.D1   Australia   2011253785   12/2/2011   2011253785   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
AMTK.P0002AU.D2   Australia   2013257540   11/19/2013   2013257540   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
AMTK.P0002AU.D3   Australia   2015202319   5/6/2015   2015202319   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
AMTK.P0002AU.D4   Australia   2017206234   7/20/2017   2017206234   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
AMTK.P0002AU.D5   Australia   2018220112   8/23/2018   2018220112   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
AMTK.P0002CN.D1   China   201110261353.3   8/9/2011   ZL 201110261353.3   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR

 

-11-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0002JP .D1   Japan   2012-241637   11/1/2012   6151006   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
AMTK.P0002JP.D2   Japan   2015-080729   4/10/2015       METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
AMTK.P0002JP.D3   Japan   2017-184649   9/26/2017   6676022   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
AMTK.P0002JP.D3D1   Japan   2020-000328   1/6/2020       METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
AMTK.P0002JP.D4   Japan   2017-184650   9/26/2017       METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
AMTK.P0002US.C1   United States of America   13/185472   7/18/2011   9138460   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0002US.D1   United States of America   12/775720   5/7/2010   8728495  

METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING

AN IN VIVO

 

-12-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
                    BIOREACTOR
AMTK.P0002US.D2   United States of America   12/775736   5/7/2010   9545432   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0002US.D2C1   United States of America   15/371994   12/7/2016   10052410   METHODSAND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0002US.D2C2   United States of America   16/038915   7/18/2018   10806824   METHODSAND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0002US.D2C3   United States of America   16/865926   5/4/2020       METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0002US.D3   United States of America   12/775753   5/7/2010   8298560   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0002US.D4   United States of America   12/775765   5/7/2010   9320776   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR

 

-13-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0002US.D5   United States of America   12/775771   5/7/2010   9533024   METHODSAND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0003CN   China   201280063195.3   6/20/2014       FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003CN.D1   China   201711263200.6   12/5/2017       FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003ECH   Switzerland   12846950.9       2776556   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003ECH.D1   Switzerland   17192969.8       3290511   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003EDE   Germany   12846950.9       2776556   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003EDE.D1   Germany   17192969.8       3290511   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003EES   Spain   12846950.9       2776556   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003EES.DI   Spain   17192969.8       3290511   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE

 

-14-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0003EFR   France   12846950.9       2776556   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003EFR.D1   France   17192969.8       3290511   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003EGB   United Kingdom   12846950.9       2776556   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003EGB.D1   United Kingdom   17192969.8       3290511   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003EHK   Hong Kong   14111200.7   11/4/2014   HKl 197832   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003EHK.D1   Hong Kong   18111368.1   9/5/2018   HK1252036   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003EIE.D1   Ireland   17192969.8       3290511   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003 EIT   Italy   12846950.9       2776556   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003EIT.D1   Italy   17192969.8       3290511   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003EP   European Patent   12846950.9   5/21/2014   2776556   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC

 

-15-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
    Office               DISEASE
AMTK.P0003EP.Dl   European Patent Office   17192969.8   9/25/2017   3290511   FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003EP.D2   European Patent Office   20186304.0   7/16/2020       FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003IN   India   391 l/DELNP/2014   5/15/2014       FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003US   United States of America   14/357558   5/9/2014       FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003US.D 1   United States of America   15/957741   4/19/2018       FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003US.Pl   United States of America   61/557479   11/9/2011       FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003US.P2   United States of America   61/691391   8/21/2012       FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0003WO   Patent Cooperation Treaty   PCT/US2012/064101   11/8/2012       FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
                     
AMTK.P0004AU   Australia   2013299505   2/2/2015   2013299505   GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS

 

-16-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0004AU.Dl   Australia   2017201708   3/13/2017   2017201708   GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS
                     
AMTK.P0004CA   Canada   2881126   2/4/2015       GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS
                     
AMTK.P0004CHK.D1   Hong Kong   42020009561.0   6/18/2020       GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS
                     
AMTK.P0004CN   China   201380047210.X   3/11/2015       GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS
                     
AMTK.P0004CN.D1   China   201911186070.X   11/28/2019       GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS
                     
AMTK.P0004EHK   Hong Kong   15110635.3   10/28/2015       GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS
                     
AMTK.P0004EP   European Patent Office   13827360.2   3/4/2015       GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS
                     
AMTK.P0004IN   India   1321/DELNP/2015   2/18/2015       GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS
                     
AMTK.P0004JP   Japan   2015-526709   2/9/2015   6456826   GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS
                     
AMTK.P0004JP .D1   Japan   2018-032337   2/26/2018   6574502   GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS
                     
AMTK.P0004JP .D2   Japan   2019-149332   8/16/2019       GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS
                     
AMTK.P0004US   United States of America   13/962241   8/8/2013       GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS

 

-17-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0004US.P1   United States of America   61/681731   8/10/2012       GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS
                     
AMTK.P0004 WO   Patent Cooperation Treaty   PCT/US2013/054158   8/8/2013       GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS
                     
AMTK.P0005AU   Australia   2014281818   12/7/2015   2014281818   ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005AU.D1   Australia   2019253856   10/23/2019       ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005CA   Canada   2915249   12/11/2015       ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005CN   China   201480039060.2   1/8/2016       ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005ECH   Switzerland   14813201.2       3011015   ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005EDE   Germany   14813201.2       3011015   ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005EES   Spain   14813201.2       3011015   ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005EFR   France   14813201.2       301’1015   ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005EGB   United Kingdom   14813201.2       3011015   ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005EHK   Hong Kong   16110257.9   8/29/2016       ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS

 

-18-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0005EIE   Ireland   14813201.2       3011015   ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005EIT   Italy   14813201.2       3011015   ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005EP   European Patent Office   14813201.2   1/6/2016   3011015   ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005IN   India   201617001725   1/18/2016       ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005JP   Japan   2016-521475   12/18/2015       ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005JP.D1   Japan   2020-119475   7/10/2020       ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005US   United States of America   14/304247   6/13/2014   10206954   ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005US.Cl   United States of America   16/244333   1/10/2019       ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005US.P1   United States of America   61/836975   6/19/2013       ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0005WO   Patent Cooperation Treaty   PCT/US2014/042322   6/13/2014       ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS
                     
AMTK.P0006AU   Australia   2014317861   3/8/2016   2014317861   GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS

 

-19-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0006AU.Dl   Australia   2019268095   11/20/2019       GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0006CA   Canada   2923857   3/9/2016       GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0006CN   China   201480057130.7   4/18/2016       GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0006EHK   Hong Kong   16112454.6   10/28/2016       GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0006EP   European Patent Office   14841529.2   4/5/2016       GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0006IN   India   201617011955   4/5/2016       GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0006JP   Japan   2016-542044   3/9/2016       GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0006JP .D1   Japan   2020-033592   2/28/2020       GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS

 

-20-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0006US   United States of America   14/917560   3/8/2016       GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0006US.Pl   United States of America   61/875509   9/9/2013       GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0006WO   Patent Cooperation Treaty   PCT/US2014/054804   9/9/2014       GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0007 AU   Australia   2017207445   7/3/2018       CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTESOR CARTILAGE TYPE CELLS
                     
AMTK.P0007CA   Canada   3011306   7/11/2018       CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0007CN   China   201780011692.1   8/16/2018       CELLULAR BLEND. FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0007EHK   Hong Kong   18115243.3   11/28/2018       CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS

 

-21-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0007EP   European Patent Office   17739050.7   7/12/2018       CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTESOR CARTILAGE TYPE CELLS
                     
AMTK.P0007IN   India   201817025735   7/10/2018       CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0007JP   Japan   2018-536724   7/13/2018       CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0007US   United States of America   16/068096   7/3/2018       CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTESOR CARTILAGE TYPE CELLS
                     
AMTK.P0007US.Pl   United States of America   62/278635   1/14/2016       CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0007US.P2   United States of America   62/413587   10/27/2016       CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
                     
AMTK.P0007WO   Patent Cooperation Treaty   PCT/US2017/013449   1/13/2017       CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTESOR CARTILAGE TYPE

 

-22-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                    CELLS
AMTK.P0008CA.D1   Canada   2925550   3/30/2016   2925550   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0008CA.D2   Canada   3019254   10/1/2018   3019254   USE OF CHONDROCYTE-LIKE CELLS TO TREAT A JOINT IN NEED OF REPAIR
                     
AMTK.P0008ECH   Switzerland   07763383.2       1989289   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0008ECH.D 1   Switzerland   16195838.4       3146939   METHODSAND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0008EDE   Germany   07763383.2       1989289   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0008EDE.D1   Germany   16195838.4       3146939   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR

 

-23-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0008EES   Spain   07763383.2       1989289   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0008EES.D1   Spain   16195838.4       3146939   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0008EFR   France   07763383.2       1989289   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0008EFR.D1   France   16195838.4       3146939   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0008EGB   United Kingdom   07763383.2       1989289   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0008EGB.D1   United Kingdom   16195838.4       3146939   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0008EHK.D1   Hong Kong   17108880.7   9/4/2017   HK1236375  

METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING

AN IN VIVO

 

-24-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
                    BIOREACTOR
AMTK.P0008EIT   Italy   07763383.2       1989289   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0008EIT.D1   Italy   16195838.4       3146939   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P0008EP.Dl   European Patent Office   16195838.4   10/26/2016   3146939   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
AMTK.P00 l 7EP   European Patent Office   19795975.2   11/23/2020       FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS
                     
AMTK.P00 l 7US   United States of America   17/052830   11/4/2020       FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS
                     
AMTK.P0017US.Pl   United States of America   62/666786   5/4/2018       FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS
                     
AMTK.P00 l 7WO   Patent Cooperation Treaty   PCT/US2019/030585   5/3/2019       FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS

 

-25-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P00 l 8EP   European Patent Office   19795797.0   11/23/2020       DE-DIFFERENTIATED FIBROBLAST- CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION
                     
AMTK.P00 l 8US   United States of America   17/052841   11/4/2020       DE-DIFFERENTIATED FIBROBLAST- CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION
                     
AMTK.P00 l 8US.Pl   United States of America   62/666777   5/4/2018       DE-DIFFERENTIATED FIBROBLAST- CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION
                     
AMTK.P00 l 8WO   Patent Cooperation Treaty   PCT/US2019/030570   5/3/2019       DE-DIFFERENTIATED FIBROBLAST- CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION
                     
AMTK.P00 l 9EHK   Hong Kong               INTRADISCAL T- REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE
                     
AMTK.P00 l 9EP   European Patent Office   19796226.9   11/24/2020       INTRADISCAL T- REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE

 

-26-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P00 l 9US   United States of America   17/052845   11/4/2020       INTRADISCAL T- REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE
                     
AMTK.P00 l 9US.Pl   United States of America   62/666807   5/4/2018       INTRADISCAL T REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE
                     
AMTK.P0019WO   Patent Cooperation Treaty   PCT/US2019/030564   5/3/2019       INTRADISCAL T- REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE
                     
AMTK.P0020EP   European Patent Office   19796689.8   11/24/2020       ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION
                     
AMTK.P0020US   United States of America   17/052854   11/4/2020       ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION
                     
AMTK.P0020US.P1   United States of America   62/666816   5/4/2018       ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION
                     
AMTK.P0020WO   Patent Cooperation Treaty   PCT/US2019/030577   5/3/2019       ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION

 

-27-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0025AU   Australia   2019332928   3/11/2021       CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER
                     
AMTK.P0025CA   Canada   3111213   2/26/2021       CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER
                     
AMTK.P0025EP   European Patent Office   19853816.7   3/24/2021       CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER
                     
AMTK.P0025US   United States of America   17/271529   2/25/2021       CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER
                     
AMTK.P0025US.Pl   United States of America   62/723105   8/27/2018       CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER
                     
AMTK.P0025US.P2   United States of America   62/820636   3/19/2019       CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER
                     
AMTK.P0025WO   Patent Cooperation Treaty   PCT/US2019/0483l l   8/27/2019       CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER

 

-28-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0033US.Pl   United States of America   62/793545   1/17/2019       FIBROBLASTS AND MACROVESICLES THEREOF FOR REDUCTION OF TOXICITY ASSOCIATED WITH CANCER INNUMOTHERAPY
                     
AMTK.P0033WO   Patent Cooperation Treaty   PCT/US2020/014018   1/17/2020       FIBROBLASTS AND MICROVESICLES THEREOF FOR REDUCTION OF TOXICITY ASSOCIATED WITH CANCER INNUMOTHERAPY
                     
AMTK.P0039US.Pl   United States of America   62/839716   4/28/2019       FIBROBLAST CELL THERAPY FOR TREATMENT OF OSTEOPOROSIS
                     
AMTK.P0039WO   Patent Cooperation Treaty   PCT/US2020/030063   4/27/2020       FIBROBLAST CELL THERAPY FOR TREATMENT OF OSTEOPOROSIS
                     
AMTK.P004 l US.Pl   United States of America   62/929828   11/2/2019       FIBROBLAST- DERIVED UNIVERSAL IMMUNOLOGICAL COMPOSITION
                     
AMTK.P004 l WO   Patent Cooperation Treaty   PCT/US2020/058492   11/2/2020       FIBROBLAST- DERIVED UNIVERSAL IMMUNOLOGICAL COMPOSITION

 

-29-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0042US   United States of America   17/022897   9/16/2020       TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGL YCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF
                     
AMTK.P0042US.Pl   United States of America   62/901164   9/16/2019       TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF
                     
AMTK.P0042WO   Patent Cooperation Treaty   PCT/US2020/051036   9/16/2020       TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF
                     
AMTK.P0044US.Pl   United States of America   62/929830   11/2/2019       INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS
                     
AMTK.P0044 WO   Patent Cooperation Treaty   PCT/US2020/058497   11/2/2020       INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS

 

-30-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
AMTK.P0045US.Pl   United States of America               FIBROBLAST DELIVERY OF HYPERACUTE REJECTION INDUCING PAYLOAD TO CANCER CELLS
                     
AMTK.P0048US.P1   United States of America   62/953841   12/26/2019       AUGMENTATION OF FIBROBLAST MEDIATED REGENERATION OF INTRAVERTEBRAL DISCS
                     
AMTK.P0048WO   Patent Cooperation Treaty   PCT/US2020/067225   12/28/2020       AUGMENTATION OF FIBROBLAST MEDIATED REGENERATION OF INTRAVERTEBRAL DISCS
                     
AMTK.P0054US.Pl   United States of America   62/914523   10/13/2019       CANNABIDIOL ADJUVANT THERAPY FOR TREATMENT OF DISC DEGENERATIVE DISEASE
                     
AMTK.P0054WO   Patent Cooperation Treaty   PCT/US2020/055313   10/13/2020       CANNABIDIOL ADJUVANT THERAPY FOR TREATMENT OF DISC DEGENERATIVE DISEASE
                     
AMTK.P0055US   United States of America   16887720   5/29/2020       CONCURRENT ACTIVATION OF REGENERATIVE AND TOLEROGENIC PROCESSES BY FIBROBLAST-BASED COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
                     
AMTK.P0055US.Pl   United States of America   62855010   5/31/2019      

CONCURRENT ACTIVATION OF REGENERATIVE AND

TOLEROGENIC

 

-31-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
                    PROCESSES BY FIBROBLAST-BASED COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
AMTK.P0055WO   Patent Cooperation Treaty   PCT/US2020/035234   5/29/2020       CONCURRENT ACTIVATION OF REGENERATIVE AND TOLEROGENIC PROCESSES BY FIBROBLAST-BASED COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
                     
AMTK.P006 l US.Pl   United States of America   62/977604   2/17/2020       TELOMERE LENGTH MODULATION USING FIBROBLASTS AND DERIVITAVES THEREOF
                     
AMTK.P0061 WO   Patent Cooperation Treaty   PCT/US2021/018160   2/16/2021       TELOMERE LENGTH MODULATION USING FIBROBLASTS
                     
AMTK.P0074US.Pl   United States of America   63/017918   4/30/2020       IMMUNOTHERAPEUTI C METHODS AND COMPOSITIONS FOR TARGETING CANCER FIBROBLASTS
                     
AMTK.P0074WO   Patent Cooperation Treaty   PCT/US2021/070496   4/30/2021       IMMUNOTHERAPEUTI C METHODS AND COMPOSITIONS FOR TARGETING CANCER FIBROBLASTS
                     
AMTK.P0077US.Pl   United States of America       Closed duplicate case       CANCER FIBROBLAST SPECIFIC CANCER IMMUNOTHERAPY
                     
P03351AU0   Australia   2007212085   7/29/2008   2007212085  

METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING

AN IN VIVO

 

-32-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                    BIOREACTOR
P03351CA0   Canada   2641170   7/25/2008   2641170   METHODS AND COMPOSITJONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
P03351CN0   China   200780004506.8   7/31/2008   ZL 200780004506.8   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
P03351EP0   European Patent Office   07763383.2   9/2/2008   1989289   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
P03351HK0   Hong Kong   09104307.l   5/11/2009   HKl 125406   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
P03351IN0   India   690 l/DELNP/2008   8/12/2008       METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
P03351JP0   Japan   2008-554464   8/6/2008   5269612   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR

 

-33-

 

 

Docket Number   Country   Appl. No.   Date Filed   Reg. No.   Title
                     
P03351US0   United States of America   60/771172   2/7/2006       METHOD FOR REPAIRING AN INTERVERTEBRAL DISC
                     
P0335 l US1   United States of America   11/671082   2/5/2007   7850983   METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR
                     
P03351WO0   Patent Cooperation Treaty   PCT/US2007/061590   2/5/2007       METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR

 

[End of Schedule 1.}

 

-34-

 

 

Schedule 2

 

SpinalCyte Licensed IP

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0009AU   Australia   2018207541   7/16/2019       METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY
                     
AMTK.P0009CA   Canada   3049768   7/9/2019       METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY
                     
AMTK.P0009CN   China   201880013348.0   8/22/2019       METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY
                     
AMTK.P0009EHK   Hong Kong   62020004216.1   3/13/2020       METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY
                     
AMTK.P0009EP   European Patent Office   18738916.8   7/24/2019       METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY
                     
AMTK.P0009IN   India   201917032228   8/8/2019       METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY
                     
AMTK.P0009JP   Japan   2019-558339   7/10/2019       METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY
                     
AMTK.P0009US   United States of America   15/868420   1/11/2018       METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY
                     
AMTK.P0009US.Cl   United States of America               METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY

 

-35-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0009US.Pl   United States of America   62/445133   1/11/2017       METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY
                     
AMTK.P0009WO   Patent Cooperation Treaty   PCT/US2018/013357   1/11/2018  

 

 

 

 

 

 

;

   METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY
                     
AMTK.P00l0AU   Australia   2018254498   9/17/2019       STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES
                     
AMTK.P00lOCA   Canada   3058783   10/1/2019       STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES
                     
AMTK.PO0lOCHK   Hong Kong   62020007292.9   5/12/2020       STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES
                     
AMTK.P00lOCN   China   201880025815.1   10/18/2019       STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES
                     
AMTK.P00lOEP   European Patent Office   18787206.4   10/8/2019       STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES
                     
AMTK.P00l0IN   India   201917042021   10/17/2019       STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES
                     
AMTK.P00lOJP   Japan   2019-556899   10/18/2019       STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES
                     
AMTK.P00lOUS   United States of America   16/495371   9/18/2019       STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES

 

-36-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P00l0US.Pl   United States of America   62/487143   4/19/2017       STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES
                     
AMTK.P00l0WO   Patent Cooperation Treaty   PCT/US2018/028358   4/19/2018       STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES
                     
AMTK.P00llAU   Australia   2018375151   5/20/2020      

INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES

THEREOF

                     
AMTK.P00llCA   Canada   3083354   5/22/2020      

INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES

THEREOF

                     
AMTK.P00llCHK   Hong Kong   62020021460.4   12/2/2020      

INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES

THEREOF

                     
AMTK.P00llCN   China   201880086376.5   7/13/2020      

INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES

THEREOF

                     
AMTK.P00llEP   European Patent Office   18884660.4   6/5/2020      

INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES

THEREOF

                     
AMTK.P00lllN   India   202017027209   6/26/2020      

INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES

THEREOF

                     
AMTK.P00llJP   Japan   2020-529293   5/28/2020      

INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES

THEREOF

                     
AMTK.P00llUS   United States of America   16/765060   5/18/2020      

INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES

THEREOF

 

-37-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P00llUS.Pl   United States of America   62/591858   11/29/2017      

INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES

THEREOF

                     
AMTK.P0011US.P2   United States of America              

INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES

THEREOF

                     
AMTK.P00llWO   Patent Cooperation Treaty   PCT/US2018/063001   11/29/2018      

INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES

THEREOF

                     
AMTK.P0016AU   Australia   2018388979   6/22/2020      

AUGMENTATION OF FIBROBLAST REGENERATIVE

ACTIVITY

                     
AMTK.P0016CA   Canada       6/16/2020      

AUGMENTATION OF FIBROBLAST REGENERATIVE

ACTIVITY

                     
AMTK.P0016CHK   Hong Kong              

AUGMENTATION OF FIBROBLAST REGENERATIVE

ACTIVITY

                     
AMTK.P0016CN   China   201880086500.8   7/14/2020       AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY
                     
AMTK.P0016EP  

European Patent.

Office

   18892707.3   6/11/2020      

AUGMENTATION OF FIBROBLAST REGENERATIVE

ACTIVITY

                     
AMTK.P0016IN   India   202017026981   6/25/2020      

AUGMENTATION OF FIBROBLAST REGENERATIVE

ACTIVITY

                     
AMTK.P0016JP   Japan   2020-534217   6/19/2020      

AUGMENTATION OF FIBROBLAST REGENERATIVE

ACTIVITY

                     
AMTK.P0016US   United States of America   16/770495   6/5/2020      

AUGMENTATION OF FIBROBLAST REGENERATIVE

ACTIVITY

 

-38-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0016US.Pl   United States of America   62/608031   12/20/2017      

AUGMENTATION OF FIBROBLAST REGENERATIVE

ACTIVITY

                     
AMTK.P0016WO   Patent Cooperation Treaty   PCT/US2018/065931   12/17/2018      

AUGMENTATION OF FIBROBLAST REGENERATIVE

ACTIVITY

                     
AMTK.P0021CA   Canada   3099387   11/4/2020       PAIN REDUCING EFFECTS OF FIBROBLASTS AND THEREOF FOR TREATMENT OF PAIN
                     
AMTK.P0021US   United States of America   17/052859   11/4/2020       PAIN REDUCING EFFECTS OF FIBROBLASTS AND TREATMENT OF PAIN
                     
AMTK.P0021US.Pl   United States of America   62/666828   5/4/2018       PAIN REDUCING EFFECTS OF FIBROBLASTS AND THEREOF FOR TREATMENT OF PAIN
                     
AMTK.P0021WO   Patent Cooperation Treaty   PCT/US2019/030596   5/3/2019       PAIN REDUCING EFFECTS OF FIBROBLASTS AND THEREOF FOR TREATMENT OF PAIN
                     
AMTK.P0022CA   Canada   3103823   12/14/2020       USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING
                     
AMTK.P0022EP   European Patent Office               USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING
                     
AMTK.P0022US   United States of America   17/251587   12/11/2020       USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING

 

-39-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0022US.Pl   United States of America   62/684844   6/14/2018       USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING
                     
AMTK.P0022WO   Patent Cooperation Treaty   PCT/US2019/037310   6/14/2019       USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING
                     
AMTK.P0023AU   Australia               METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT
                     
AMTK.P0023CA   Canada               METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT
                     
AMTK.P0023EP   European Patent Office               METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT
                     
AMTK.P0023JP   Japan               METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT

 

-40-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0023US   United States of America   17/309176   5/3/2021       METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT
                     
AMTK.P0023US.Pl   United States of America   62/755523   11/4/2018       METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT
                     
AMTK.P0023WO   Patent Cooperation Treaty   PCT/US2019/059666   11/4/2019       METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT
                     
AMTK.P0024AU   Australia               TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
                     
AMTK.P0024CA   Canada               TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
                     
AMTK.P0024EP   European Patent Office               TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
                     
AMTK.P0024JP   Japan               TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
                     
AMTK.P0024US   United States of America   17/309177   5/3/2021       TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF

 

-41-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0024US.Pl   United States of America   62/755542   11/4/2018       TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
                     
AMTK.P0024WO   Patent Cooperation Treaty   PCT/US2019/059678   11/4/2019       TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
                     
AMTK.P0026AU   Australia               REGENERATIVE ABSCOPAL EFFECTS
                     
AMTK.P0026CA   Canada               REGENERATIVE ABSCOPAL EFFECTS
                     
AMTK.P0026EP  

European

Patent Office

   19881814.8           REGENERATIVE ABSCOPAL EFFECTS
                     
AMTK.P0026JP   Japan               REGENERATIVE ABSCOPAL EFFECTS
                     
AMTK.P0026US  

United

States of America

   17/309207   5/6/2021       REGENERATIVE ABSCOPAL EFFECTS
                     
AMTK.P0026US.Pl   United States of America   62/757764   11/9/2018       REGENERATIVE ABSCOPAL EFFECTS
                     
AMTK.P0026WO  

Patent

Cooperation Treaty

   PCT/US2019/060397   11/8/2019       REGENERATIVE ABSCOPAL EFFECTS
                     
AMTK.P0028AU   Australia               MEANS AND METHODS OF PREVENTING OR REVERSING AGING
                     
AMTK.P0028CA   Canada               MEANS AND METHODS OF PREVENTING OR REVERSING AGING
                     
AMTK.P0028EP   European Patent Office   19882270.2           MEANS AND METHODS OF PREVENTING OR REVERSING AGING
                     
AMTK.P0028JP   Japan               MEANS AND METHODS OF PREVENTING OR REVERSING AGING
                     
AMTK.P0028US   United States of America   17/309208   5/6/2021       MEANS AND METHODS OF PREVENTING OR REVERSING AGING
                     
AMTK.P0028US.Pl   United States of America   62/758240   11/9/2018       MEANS AND METHODS OF PREVENTING OR REVERSING AGING

 

-42-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0028WO   Patent Cooperation Treaty   PCT/US2019/060446   11/8/2019       MEANS AND METHODS OF PREVENTING OR REVERSING AGING
                     
AMTK.P0029US.Pl  

United States of

America

   62/791207   1/11/2019       FIBROBLAST REGENERATIVE CELLS
                     
AMTK.P0029WO  

Patent Cooperation

Treaty

   PCT/US2020/013315   1/13/2020       FIBROBLAST REGENERATIVE CELLS
                     
AMTK.P0030US.Pl   United States of America   62/839644   4/27/2019       SELECTION OF FIBROBLAST DONORS FOR OPTIMIZATION OF ALLOGENEIC FIBROBLAST MEDIATED REGENERATION
                     
AMTK.P0030WO   Patent Cooperation Treaty   PCT/US2020/030041   4/27/2020       SELECTION OF FIBROBLAST DONORS FOR OPTIMIZATION OF ALLOGENEIC FIBROBLAST MEDIATED REGENERATION
                     
AMTK.P0031US.Pl  

United States of

America

   62/780289   12/16/2018       THERAPEUTIC USES OF GENE EDITED FIBROBLASTS
                     
AMTK.P0031WO   Patent Cooperation Treaty   PCT/US2019/066575   12/16/2019       THERAPEUTIC USES OF GENE EDITED FIBROBLASTS
                     
AMTK.P0032AU   Australia               TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY
                     
AMTK.P0032CA   Canada               TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY

 

-43-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0032EP   European Patent Office               TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY
                     
AMTK.P0032JP   Japan               TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY
                     
AMTK.P0032US   United States of America   17/309178   5/3/2021       TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY
                     
AMTK.P0032US.Pl   United States of America   62/755553   11/4/2018       TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY
                     
AMTK.P0032WO   Patent Cooperation Treaty   PCT/US2019/059683   11/4/2019       TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY
                     
AMTK.P0034US   United States of America   16/822746   3/18/2020       TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF
                     
AMTK.P0034US.Pl   United States of America   62/820721   3/19/2019       TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF

 

-44-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0034WO   Patent Cooperation Treaty   PCT/US2020/023332   3/18/2020       TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF
                     
AMTK.P0035US   United   16/913860   6/26/2020       ADMINISTRATION OF
    States of               FIBROBLASTS AND
    America               DERIVATIVES THEREOF
                    FOR TREATMENT OF
                    TYPE 2 DIABETES
                     
AMTK.P0035US.Pl   United   62/867976   6/28/2019       ADMINISTRATION OF
    States of               FIBROBLASTS AND
    America               DERIVATIVES THEREOF
                    FOR TREATMENT OF
                    TYPE 2 DIABETES
                     
AMTK.P0035WO   Patent   PCT/US2020/039904   6/26/2020       ADMINISTRATION OF
    Cooperation               FIBROBLASTS AND
    Treaty               DERIVATIVES THEREOF
                    FOR TREATMENT OF
                    TYPE 2 DIABETES
                     
AMTK.P0036US   United States of America   16/822811   3/18/2020      

TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

AND LUNG

                     
                   

DEGENERATION USING

ACTIVATED

                     
                   

FIBROBLASTS AND

EXOSOME DERIVATIVES THEREOF

                     
AMTK.P0036US.Pl   United   62/820763   3/19/2019       TREATMENT OF
    States of               CHRONIC
    America               OBSTRUCTIVE
                    PULMONARY DISEASE
                    AND LUNG
                    DEGENERATION USING
                    ACTIVATED
                    FIBROBLASTS AND
                    EXOSOME DERIVATIVES
                    THEREOF

 

-45-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0036WO   Patent Cooperation Treaty   PCT/US2020/023339   3/18/2020      

TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG

DEGENERATION USING

                   

ACTIVATED FIBROBLASTS AND EXOSOME DERIVATIVES

THEREOF

                     
AMTK.P0037US.Pl   United States of America   62/845403   5/9/2019       FIBROBLAST GENERATED PATIENT SPECIFIC VACCINES
                     
AMTK.P0037WO   Patent Cooperation Treaty   PCT/US2020/032207   5/8/2020       FIBROBLAST GENERATED PATIENT- SPECIFIC VACCINES
                     
AMTK.P0038US.Pl   United States of   62/839652   4/27/2019       ENHANCEMENT OF FIBROBLAST
    America              

THERAPEUTIC ACTIVITY

BY T CELL MODULATION

                     
AMTK.P0038WO   Patent   PCT/US2020/030045   4/27/2020       ENHANCEMENT OF
    Cooperation               FIBROBLAST
    Treaty               THERAPEUTIC ACTIVITY
                    BY T CELL
                    MODULATION
                     
AMTK.P0040US.Pl   United   62/860252   6/12/2019       ENHANCEMENT OF
    States of               FIBROBLAST
    America               THERAPEUTIC ACTIVITY
                    BY
                    RNA
                     
AMTK.P0040WO   Patent   PCT/US2020/037467   6/12/2020       ENHANCEMENT OF
    Cooperation               FIBROBLAST
    Treaty               THERAPEUTIC ACTIVITY
                    BY
                    RNA
                     
AMTK.P0043US.Pl   United   62/915292   10/15/2019       PREVENTION OF
    States of               RECURRENT
    America               MISCARRIAGES
                    THROUGH
                    ADMINISTRATION OF
                    FIBROBLAST AND
                    FIBROBLAST EDUCATED
                    PATERNAL CELLS

 

-46-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0043WO   Patent Cooperation Treaty   PCT/US2020/055642   10/14/2020      

PREVENTION OF RECURRENT MISCARRIAGES THROUGH ADMINISTRATION OF

FIBROBLAST AND

                    FIBROBLAST EDUCATED PATERNAL CELLS
                     
AMTK.P0046US.Pl   United   62/953836   12/26/2019       PREVENTION AND
    States of               TREATMENT OF KIDNEY
    America               FAILURE BY
                    ADMINISTRATION OF
                    FIBROBLASTS AND
                    PRODUCTS THEREOF
                     
AMTK.P0046WO   Patent   PCT/US2020/066585   12/22/2020       PREVENTION AND
    Cooperation               TREATMENT OF KIDNEY
    Treaty               FAILURE BY
                    ADMINISTRATION OF
                    FIBROBLASTS AND
                    PRODUCTS THEREOF
                     
AMTK.P0047US   United States of America   16/887971   5/29/2020       FIBROBLAST THERAPY FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
                     
AMTK.P0047US.Pl   United States of America   62/855014   5/31/2019       FIBROBLAST THERAPY FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
                     
AMTK.P0047WO   Patent Cooperation Treaty   PCT/US2020/035283   5/29/2020       FIBROBLAST THERAPY FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
                     
AMTK.P0049US.Pl   United   62/864503   6/21/2019       TREATMENT OF
    States of               AUTISM SPECTRUM
    America               DISORDER AND
                    ASSOCIATED
                    NEUROINFLAMMATION
                    USING FIBROBLASTS
                    AND DERIVATIVES
                    THEREOF

 

-47-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0049WO   Patent Cooperation Treaty   PCT/US2020/038967   6/22/2020      

TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED NEUROINFLAMMATION USING FIBROBLASTS AND DERIVATIVES

THEREOF

                     
AMTK.P0050US.Pl   United States of America   62/953843   12/26/2019      

SUPRESSION OF INTERLEUKIN-17 PRODUCTION AND INHIBITION OF Th17 CELL GENERATION BY

FIBROBLASTS AND PRODUCTS THEREOF

                     
AMTK.P0050WO   Patent Cooperation Treaty   PCT/US2020/066591   12/22/2020       SUPRESSION OF INTERLEUKIN-17 PRODUCTION AND INHIBITION OF Th17 CELL GENERATION BY FIBROBLASTS AND PRODUCTS THEREOF
                     
AMTK.P0051US.Pl   United States of America   62/953847   12/26/2019       INHIBITION OF TNF- ALPHA BY FIBROBLASTS AND FIBROBLAST EXOSOMES
                     
AMTK.P0051WO   Patent Cooperation Treaty   PCT/US2020/066602   12/22/2020       INHIBITION OF TNF- ALPHA BY FIBROBLASTS AND FIBROBLAST EXOSOMES
                     
AMTK.P0052US.Pl   United States of America   62/915152   10/15/2019       FIBROBLAST- BASED IMMUNOTHERAPY OF GRAVES DISEASE
                     
AMTK.P0052WO   Patent Cooperation Treaty   PCT/US2020/055641   10/14/2020       FIBROBLAST - BASED IMMUNOTHERAPY OF GRAVES DISEASE
                     
AMTK.P0053US.Pl   United States of America   62/935678   11/15/2019       FIBROBLAST THERAPY FOR INFLAMMATORY BOWEL DISEASE
                     
AMTK.P0053WO   Patent Cooperation Treaty   PCT/US2020/060748   11/16/2020       FIBROBLAST THERAPY FOR INFLAMMATORY BOWEL DISEASE

 

-48-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0057US.Pl   United States of America   62/914747   10/14/2019       TREATMENT OF AUTOIMMUNITY AND TRANSPLANT REJECTION THROUGH ESTABLISHMENT AND/OR PROMOTION OF TOLEROGENIC PROCESSES BY FlBROBLAST-M EDIATED REPROGRAMMING OF ANTIGEN PRESENTING CELLS
                     
AMTK.P0057WO   Patent Cooperation Treaty   PCT/US2020/055427   10/13/2020       TREATMENT OF AUTOIMMUNITY AND TRANSPLANT REJECTION THROUGH ESTABLISHMENT AND/OR PROMOTION OF TOLEROGENIC PROCESSES BY FIBROBLAST-MEDIATED REPROGRAMMING OF ANTIGEN PRESENTING CELLS
                     
AMTK.P0058US.P1   United States of America   62/936548   11/17/2019      

FIBROBLAST-BASED THERAPY AND TREATMENT AND PREVENTION OF

STROKE

                     
AMTK.P0058US.P2   United States of America   63/047813   7/2/2020      

FIBROBLAST-BASED THERAPY AND TREATMENT AND PREVENTION OF

STROKE

                     
AMTK.P0058WO   Patent Cooperation Treaty   PCT/US2020/060724   11/16/2020      

FIBROBLAST-BASED THERAPY AND TREATMENT AND PREVENTION OF

STROKE

                     
AMTK.P0059US.Pl   United States of America   62/976048   2/13/2020       TREATMENT AND PREVENTION OF CEREBRAL PALSY USING FIBROBLASTS

 

-49-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0059WO   Patent Cooperation Treaty   PCT/US2021/017998   2/12/2021       TREATMENT OF CEREBRAL PALSY USING FIBROBLASTS
                     
AMTK.P0060US.P1   United States of America   62/929250   11/1/2019      

FlBROBLAST-BASED THERAPY FOR TREATMENT OF SCLEROSING

CHOLANGITIS

                     
AMTK.P0060WO   Patent Cooperation Treaty   PCT/US2020/058500   11/2/2020      

FIBROBLAST-BASED THERAPY FOR TREATMENT OF SCLEROSING

CHOLANGITIS

                     
AMTK.P0062US.Pl   United States of America   63/024440   5/13/2020       FIBROBLAST BASED CELL THERAPY FOR TREATMENT OF PARKINSON’S DISEASE
                     
AMTK.P0062WO   Patent Cooperation Treaty   PCT/US2021/070551   5/13/2021       FIBROBLAST BASED CELL THERAPY FOR TREATMENT OF PARKINSON’S DISEASE
                     
AMTK.P0063US.P1   United States of America   63/008970   4/13/2020      

TREATMENT OF ERECTILE DYSFUNCTION BY FIBROBLAST

ADMINISTRATION

                     
AMTK.P0063WO   Patent Cooperation Treaty   PCT/US2021/026752   4/10/2021      

TREATMENT OF ERECTILE DYSFUNCTION BY FIBROBLAST

ADMINISTRATION

                     
AMTK.P0064US.Pl   United States of America   63/006957   4/8/2020       METHODS AND COMPOSITIONS FOR ALLERGY AND ASTHMA TREATMENT USING FIBROBLASTS
                     
AMTK.P0064WO   Patent Cooperation Treaty   PCT/US2021/025959   4/6/2021       METHODS AND COMPOSITIONS FOR ALLERGY AND ASTHMA TREATMENT USING FIBROBLASTS

 

-50-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0065US.P1   United States of America   62/897428   9/9/2019      

FIBROBLAST AND FIBROBLAST- IMMUNOCYTE COMBINATIONS FOR TREATMENT OF

SUBCONCUSSIVE- AND

                   

CONCUSSIVE

ASSOCIATED NEUROLOGICAL

                    DAMAGE
AMTK.P0065WO   Patent   PCT/US2020/049949   9/9/2020       FIBROBLAST AND
    Cooperation               FIBROBLAST-
    Treaty               IMMUNOCYTE
                    COMBINATIONS FOR
                    TREATMENT OF
                    SUBCONCUSSIVE- AND
                    CONCUSSIVE
                    ASSOCIATED
                    NEUROLOGICAL
                    DAMAGE
                     
AMTK.P0066US.Pl   United   62/897429   9/9/2019       TREATMENT OF
    States of               TRAUMATIC
    America               ENCEPHALOPATHY BY
                    FIBROBLASTS AND
                    THERAPEUTIC
                    ADJUVANTS
                     
AMTK.P0066WO   Patent   PCT/US2020/049990   9/9/2020       TREATMENT OF
    Cooperation               TRAUMATIC
    Treaty               ENCEPHALOPATHY BY
                    FIBROBLASTS AND
                    THERAPEUTIC
                    ADJUVANTS
                     
AMTK.POOG7 US.P1   United   63/033092   6/1/2020       FIBROBLASTS AS A
    States of               REGENERATIVE
    America               CELLULAR SOURCE FOR
                    TREATMENT OF
                    BLINDNESS
                     
AMTK.P0067WO   Patent               FIBROBLASTS AS A
    Cooperation               REGENERATIVE
    Treaty               CELLULAR SOURCE FOR
                    TREATMENT OF
                    BLINDNESS
                     
 AMTK.P0068US.P1   United   63/015150   4/24/2020       TREATMENT OF
    States of               FRONTOTEMPORAL
    America               DEMENTIA USING
                    FIBROBLASTS AND
                    PRODUCTS THEREOF

 

-51-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0068WO   Patent Cooperation Treaty   PCT/US2021/027980   4/19/2021       TREATMENT OF FRONTOTEMPORAL DEMENTIA USING FIBROBLASTS AND PRODUCTS THEREOF
                     
AMTK.P0069US.Pl   United States of America   63/012200   4/19/2020       MEANS AND METHODS OF AUGMENTATION OF FIBROBLAST THERAPEUTIC PROPERTIES USING EXTRACORPOREAL SHOCK WAVE THERAPY AND/OR TRANSFECTION OF BIOLOGICALLY RELEVANT MOLECULES
                     
AMTK.P0069WO   Patent Cooperation Treaty   PCT/US2021/027654   4/16/2021       MEANS AND METHODS OF AUGMENTATION OF FIBROBLAST THERAPEUTIC PROPERTIES USING EXTRACORPOREAL SHOCK WAVE THERAPY AND/OR TRANSFECTION OF BIOLOGICALLY RELEVANT MOLECULES
                     
AMTK.P0070US.P1   United States of America   63/031782   5/29/2020       FIBROBLAST THERAPY FOR PREVENTION AND REVERSION OF ANEURYSMS
                     
AMTK.P0070WO   Patent Cooperation Treaty               FIBROBLAST THERAPY FOR PREVENTION AND REVERSION OF ANEURYSMS
                     
AMTK.P0071US.P1   United States of America   63/025092   5/14/2020       TREATMENT OF OVARIAN FAILURE USING REGENERATIVE CELLS
                     
AMTK.P0071WO   Patent Cooperation Treaty   PCT/US2021/070555   5/14/2021       TREATMENT OF OVARIAN FAILURE USING REGENERATIVE CELLS

 

-52-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0072US.Pl   United States of America   63/031810   5/29/2020      

AUGMENTATION OF FIBROBLAST CELL THERAPY EFFICACY BY MICROBIOME

MANIPULATION

                     
AMTK.P0072WO   Patent Cooperation Treaty              

AUGMENTATION OF FIBROBLAST CELL THERAPY EFFICACY BY MICROBIOME

MANIPULATION

                     
AMTK.P0073US.Pl   United States of America               TREATMENT OF CEREBRAL HEMORRHAGE USING FIBROBLASTS, MODIFIED FIBROBLASTS AND DERIVATIVES THEREOF
                     
AMTK.P0075 US.Pl   United States of America   63/012202   4/19/2020      

GENE MODIFIED FIBROBLASTS FOR THERAPEUTIC

APPLICATIONS

                     
AMTK.P0075WO   Patent Cooperation Treaty   PCT/US2021/027990   4/19/2021      

GENE MODIFIED FIBROBLASTS FOR THERAPEUTIC

APPLICATIONS

                     
AMTK.P0076US.Pl   United States of America   62/986339   3/6/2020       FIBROBLAST AND TLR ACTIVATED FIBROBLAST TREATMENT OF VIRAL INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME
                     
AMTK.P0076WO   Patent Cooperation Treaty   PCT/US2021/020449   3/2/2021       FIBROBLAST AND TLR ACTIVATED FIBROBLAST TREATMENT OF VIRAL INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME
                     
AMTK.P0078US.Pl   United States of America   62/989118   3/13/2020       GENERATION OF AUTOIMMUNE INHIBITORY T CELLS BY FIBROBLAST MEDIATED EDUCATION

 

-53-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0078WO   Patent Cooperation Treaty   PCT/US2021/022145   3/12/2021       GENERATION OF AUTOIMMUNE INHIBITORY T CELLS BY FIBROBLAST MEDIATED EDUCATION
                     
AMTK.P0079US.Pl   United States of America   63/002134   3/30/2020       PEPTIDES AND ADJUVANTS FOR AUGMENTATION OF FIBROBLAST THERAPY FOR CORONAVIRUS
                     
AMTK.P0079US.P2   United States of America   63/003742   4/1/2020       PEPTIDES AND ADJUVANTS FOR AUGMENTATION OF FIBROBLAST THERAPY FOR CORONAVIRUS
                     
AMTK.P0079WO   Patent Cooperation Treaty   PCT/US2021/020457   3/2/2021       PEPTIDES AND ADJUVANTS FOR AUGMENTATION OF FIBROBLAST THERAPY FOR CORONAVIRUS
                     
AMTK.P0080US.Pl   United States of America   63/003731   4/1/2020       FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
                     
AMTK.P0080US.P2   United States of America   63/017068   4/29/2020       FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

 

-54-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0080WO   Patent Cooperation Treaty   PCT/US2021/020459   3/2/2021       FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
                     
AMTK.P0081US.Pl   United States of America               TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME BY FIBROBLASTS AND ANTI-INFLAMMATORY ANTIGEN
                     
AMTK.P0082US.Pl   United States of America   63/020198   5/5/2020      

REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND

EXTRACTS THEREOF

                     
AMTK.P0082WO   Patent Cooperation Treaty   PCT/US2021/070504   5/4/2021      

REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND

EXTRACTS THEREOF

                     
AMTK.P0083US.Pl   United States of America   63/051845   7/14/2020       AUGMENTATION OF FIBROBLAST THERAPEUTIC ACTIVITY BY COMPLEMENT BLOCKADE AND/OR INHIBITION
                     
AMTK.P0084US.Pl   United States of America   63/071333   8/27/2020       DENTAL AND PERIODONTAL APPLICATION OF FIBROBLASTS

 

-55-

 

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
                     
AMTK.P0085US.Pl   United States of America   63/064538   8/12/2020      

Reduction of COVID-19 Coagulopathy and Other Inflammation Associated Coagulopathies by Administration of

Fibroblasts

                     
AMTK.P0086US.Pl   United             TREATMENT OF
    States of             ALOPECIA AND/OR
    America             STIMULATION OF HAIR
                  FOLLICLE
                  REGENERATION BY
                  ADMINISTRATION OF
                  FIBROBLASTS AND/OR
                  PRODUCTS THEREOF

 

[End of Schedule 2.]

 

56